Please assess the completion status of the following clinical trial:

Trial Title: Selective Complex Fractionated Atrial Electrograms (CFAE) Targeting for Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Candidates for this study must meet ALL of the following criteria:~* Age ≥ 18 years old~* First-time ablation procedure for AF~* Symptomatic AF which has been refractory to at least one antiarrhythmic medication (AAD). Symptomatic patients are those who have been aware of their AF anytime within the last 5 years. Symptoms may include, but are not restricted to, palpitations, shortness of breath, chest pain, fatigue, or other symptoms, or any combination of the above~* One of the following must apply:~  * AF must either be PERSISTENT AF (non-US sites only) or HIGH BURDEN PAROXYSMAL AF - High burden paroxysmal AF is defined as episodes that terminate within 30 days and meet any ONE of the following criteria:~ * More than 1 episode of AF per month in the preceding 6 months with at least 1 episode lasting \>24 hours by symptoms,~ * LA size of \>/= 48 mm in the PLAX (parasternal long axis) view on echocardiography~ * LA volume \>/= 100 cc~ * Total AF history \>/= 10 years~* At least one episode of AF must have been documented by ECG, Holter, TTM, or telemetry strip within 24 months of inclusion in the study.~* Patients must be able and willing to provide written informed consent to participate in the study.~* Able and willing to comply with all pre-, post- and follow-up testing and requirements.~Exclusion Criteria:~Candidates will be excluded from the study if any of the following conditions apply:~* Patients with long-standing persistent AF \>1 year for which cardioversion (pharmacologic or electrical) has failed or will never be attempted.~* Patients with AF felt to be secondary to an obvious reversible cause.~* Patients with contraindications to systemic anticoagulation with heparin or Coumadin.~* Patients who have previously undergone atrial fibrillation ablation.~* Patients who are pregnant (by history of menses or pregnancy test if history is considered unreliable.~* Left atrial size ≥55 mm (PLAX view on echocardiography).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- (1) targeted CFAE ablation (Type: ACTIVE_COMPARATOR): None
- (2) generalized CFAE ablation (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).